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Elevated serum uric acid (hyperuricemia) increases the risk for gout, renal and 
cardiovascular disease. Hyperuricemia also induces inflammation in human smooth muscle and 
endothelial cells, reflected in the upregulation of C-reactive protein (CRP), an acute-phase 
reactant. Sugar-sweetened beverages (SSBs) increase SUA and CRP concentrations. However, it 
is not clear if SUA and/or CRP response to SSB is dependent on gender, ethnicity and genotype. 
Our project’s main aim was to determine the ethnic-, gender- and genotype-specific effects of 
SSBs on SUA and CRP in Caucasian, African-American or Hispanic adults. Our study in 62 
subjects showed that following SSB consumption, SUA increased by 0.66 mg/dL within 30 
minutes and then gradually restored to baseline concentration. Throughout the intervention, SUA 
was significantly different between Caucasians and African-Americans (p<0.05) and men and 
women (p<0.01). The present data demonstrates that SUA response is mainly dependent on an 
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Sugar-sweetened beverages (SSBs) including regular soda and sport drinks are often 
sweetened with sucrose or high-fructose corn syrup (HFCS), both of which are major sources of 
dietary fructose. Frequent SSB consumers were at significantly higher risk of developing high 
uric acid (hyperuricemia) (1, 2), obesity and type 2 diabetes (2–4). 
 
Fructose metabolism and uric acid 
Fructose is a monosaccharide that is commonly found in fruits, HFCS. It is the only 
monosaccharide that raises serum uric acid (SUA) concentration (Figure 1). After gaining access 
into the jejunum by facilitative transporters glucose transporter 5 (GLUT 5) and glucose 
transporter 2 (GLUT 2), fructose is then transported in the portal vein to the liver to be 
metabolized. Fructose is phosphorylated by enzyme fructokinase-C to fructose-1-phosphate (5). 
Fructokinase-C, in contrast to hexokinase, is not regulated by feedback mechanism; therefore, 
when a large amount of fructose is consumed, adenosine triphosphate (ATP) quickly exhausts to 
supply the phosphate needed by fructokinase-C. The adenosine monophosphate (AMP) produced 
from ATP is either deaminated to inosine monophosphate (IMP) by AMP deaminase or 
dephosphorylated to adenosine by nucleotidase (5). As a result, the amount of uric acid produced 




Hyperuricemia is a risk factor for gout and other metabolic disorders 
Uric acid is a weak organic acid that is present as monosodium urate at physiological pH. 
Humans do not have the enzyme uricase to oxidize uric acid to 5-hydroxyisourate and 
subsequently to allantoin, a water-soluble excretion product that can be eliminated by the urine. 
Although it has been proposed that the evolutionary loss of uricase is a selective advantage as 
uric acid acts as an antioxidant and neuroprotector (6), without uricase to effectively lower uric 
acid concentrations, humans are vulnerable to diseases such as gout because crystals form when 
the concentrations of SUA exceed its saturation point and deposit in tissues and joints. The 
concentrations of SUA are determined not only by its production but also by its elimination. One 
thirds of the uric acid in our system can be excreted through the intestine while the remaining 
two thirds are eliminated through the kidneys, (7,8). Uric acid travels in the blood to the kidney, 
where it is filtered through the glomerulus and then travels to the renal proximal tubule. There 
are many urate transporters lining on the basolateral and apical sides of the renal proximal tubule 
that are capable of translocating uric acid in both directions. 90% of the uric acid in the kidneys 
is reabsorbed back into the bloodstream by urate transporters including solute carrier camily 2 
member 9 (SLC2A9), and 10% are excreted in the urine via efflux transporters including solute 
carrier family 17 member 1 (SLC17A1) and ATP-biding cassette subfamily G member 2 
(ABCG2) (Figure 1).    
 
High uric acid (hyperuricemia) is defined as a concentration of uric acid greater than 7 
mg/dL in men and 5.7 mg/dL in women (9). Hyperuricemia is closely allied with metabolic 
syndrome (10), hypertension and cardiovascular disease (11). Furthermore, the higher the uric 
acid level the higher the risk of developing gout (9). In a prospective cohort study, healthy men 
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who had a SUA concentrations of 9 mg/dL or more had an incidence rate of gouty arthritis of 5% 
per year, which was almost 500-times the incidence rate of those whose SUA concentrations 
were below 7.0 mg/dL (12). Gout is estimated to be present in 3.9% of the population in the 
United States, and 5.9% in men while 2.0% in women (13).  
 
SUA and inflammation 
The double bond in uric acid makes it an anti-oxidant that is capable of scavenging free 
radicals. However, earlier work conducted in human vascular cells reported that physiologically 
relevant uric acid triggered an upregulation in C-reactive protein (CRP) mRNA and proteins (14). 
There has been a debate over whether there is a causal relationship between hyperuricemia and 
CVD ((15–17) and we speculate CRP to be the link. CRP is produced in the liver as an acute-
phase response protein to nonspecific infection and inflammation (18). The median concentration 
of CRP in healthy adults is 0.08 mg/dL (19). Due to the advance of high-sensitivity assays, 
extensive studies were published demonstrating CRP as a predictive marker for future 
cardiovascular events (20,21). The relationship between fructose/SSB and CRP has also been 
explored. In an acute feeding study similar to ours, CRP increased significantly and peaked 60 
minute in subjects who consumed fructose compared to those who consumed glucose or sucrose 
(22). Similar result was also observed in a 3-week crossover study (23). 
 
 
Gender-specific effects on SUA 
 Women, compared to men of similar age, usually have a lower SUA concentration. 
Epidemiological studies have shown that both natural and surgical menopause were associated 
with increased SUA levels by 0.34 mg/dL and 0.36 mg/dL (24). Hormone use, on the other hand, 
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was associated with lower SUA levels among postmenopausal women (24–26). Furthermore, the 
uric acid levels in male-to-female transgender persons fell significantly after one year of 
hormone therapy when compared with baseline (27). Taken together, these results suggest a role 
of female hormones on uric acid levels that could be due to a higher renal excretion or a lower 
production. To this date, only a handful of studies have looked into the effects of estrogen, the 
primary female sex hormone, on SUA concentrations. Anton et al. reported that neither renal 
excretion of urate nor serum urate was influenced by estradiol-17b (28). Alternative hypotheses 
for such gender-specific difference in SUA levels include, menopause alters body fat distribution 
which leads to insulin resistance that concomitantly influences uric acid concentrations (26) and 
hyperinsulinemia lowers urinary uric acid excretion (29). 
 
Ethnic-specific effects on SUA/gout and CRP 
 An epidemiological study of 5926 subjects showed that black persons had significantly 
higher SUA levels than white persons (30), which mirrors the higher prevalence of gout in blacks 
reported in other studies (31,32). During 1988 and 1994, analysis on NHANES III revealed that 
about 32% African Americans were hyperuricemic, followed by Caucasians (29%) and Mexican 
Americans (28.8%) (33). Outside of the United States, gout was significantly more prevalent in 
New Zealand Maori (6.4%) than in Europeans (2.9%) in a cohort study (34). What worth 
noticing is that such ethnic-specific effects overlap with many risk factors for gout including 
obesity and hypertension. 
 Interestingly, a cross-sectional study in 3154 women reported differences in CRP 
concentrations after multivariate adjustments including BMI (35). In this study, African-
American women had a 37% increase in risk while East Asians were 50% less likely of having a 
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CRP concentrations higher than 0.3 mg/dL. Genetic variance of polymorphisms in CRP genes 
may explain such a difference. 
 
Genotype-specific effects on SUA 
60% of the variance in hyperuricemia is estimated to be attributable to heritable factors 
(36). A genome-wide association study (GWAS) led by Kottgen identified 28 genetic loci 
associated with SUA and gout in more than 1400,00 European descendants (37). Most of the 
genes identified encode uric acid transporters in kidneys and intestine. However, merely 7% of 
the variance in urate levels could be explained by GWAS (37), with the rest of variance 
remaining unexplained.  
 
The effects of obesity on SUA and CRP 
BMI, an indicator of body fat based on height and weight, is positively correlated with 
SUA (38–40) and CRP (35,41). Xanthine oxidoreductase (XOR), which catalyzes the conversion 
of purine to uric acid, is highly expressed in adipose tissue. Using mouse model, Tsushima et al. 
demonstrated that obese adipose tissue produced and secreted uric acid in a XOR-dependent 
manner, which was speculated to originate from obesity-related hypoxia or lipogenesis (42). 
Several investigators also proposed mechanisms by which adiposity impairs the clearance of uric 
acid that is related to insulin resistance (43,44). In these studies, hyperinsulinemia decreases 
urinary urate export coupled with a decrease in urinary sodium excretion, due to the fact that 
urate and sodium share many renal transporters (need reference). Nevertheless, an earlier study 
conducted in 36 obese and hyperuricemic men showed that visceral fat accumulation had little to 
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do with impaired urinary urate excretion, suggesting its relationship with overproduced uric acid 
(45).  
 
Although a variety of studies have been conducted in each of the aspect mentioned above 
in relationship to uric acid, none have explored the accumulative effect of gender, ethnicity, 
genotype and obesity status on SUA and CRP after a fructose challenge. To fill this gap, we 
recruited 62 subjects from three ethnicity backgrounds in this pilot study. The methods and 







































The consumption of added sugars, mostly fructose, in the United States has increased 
considerably in past few decades. As per the National Health and Examination Survey 
(NHANES) 1988 to 1994, intake of added sugars was higher in men than women and also 
highest in African-Americans followed by Hispanics and Caucasians (46). 
 
Fructose has the unique role to be the only monosaccharide that raises serum uric acid 
(SUA) concentration. Fructose is primarily metabolized in the liver, where it is phosphorylated 
by fructokinase-C to fructose-1-phosphate (5). Fructokinase-C, in contrast to hexokinase, is not 
regulated by feedback mechanism. When a large amount of fructose is consumed, adenosine 
triphosphate (ATP) is quickly exhausted to supply the phosphate needed by fructokinase-C. As a 
result, adenosine monophosphate (AMP) gets produced and is converted into uric acid by a 
series of enzymatic reactions (5). SSB intake has also been associated with increased C-reactive 
protein (CRP), an acute phase reactant (22,23). Both elevated SUA (hyperuricemia) and CRP 
increase the risk for cardiovascular disease (CVD) (17,47), however, the underlying mechanism 
linking them to CVD risk remains less clear.  
 
Serum concentrations of uric acid differ based on one’s age, gender and ethnicity. Studies 
have shown that SUA is higher in non-Hispanic blacks as compared to White individuals (30). 
Women, compared to men in the same age, tend to have lower SUA (24). Furthermore, the 
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variation in SUA concentrations is strongly influenced by genetic factors. Genetic studies have 
identified strong association of common single nucleotide polymorphisms (SNPs) in urate 
transporters with altered SUA concentrations. Out of the 12 urate transporters identified so far, 
two urate transporters, ATP-binding cassette transporter, subfamily G, member 2 (ABCG2) and 
solute carrier family 2, member 9 (SCL2A9) have been studied extensively and reported to play 
important roles in the regulation of SUA (48). 
 
Although a considerable amount of research has been conducted on fructose intake and 
subsequent uric acid production, limited is known about the ethnic- and genotype-specific effects 
of fructose load on SUA. The aim of the present study was to investigate the effect of a sugar-
sweetened beverage (SSB) containing 80% fructose on serum concentrations of uric acid and 
CRP in middle-aged adults of Caucasian, African-American or Hispanic descent. We 
hypothesized that (1) after drinking the SSB, concentrations of SUA and CRP increase rapidly 
within 30 minutes and then restore to baseline levels within 3 hours, and (2) the responses of 






The Fructose Challenge Study (FCS) is a dietary intervention study designed to 
investigate the acute effects of a fructose challenge on uric acid metabolism in adults of three 
ethnicity backgrounds. The FCS was carried out at University of North Carolina at Chapel Hill 
(UNC) Nutrition Research Institute (NRI) in Kannapolis, North Carolina. Men and women adults, 
30 to 50 yr of age, were recruited by website advertisements and fliers posted in the Kannapolis 
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area. Exclusion criteria included self-reported diabetes, chronic kidney disease (CKD) and 
fructose intolerance. The self-reported ethnicity of the subjects was as follows: 37 Caucasians, 
20 African-Americans and 5 Hispanics.  
 
Study design  
Following a 12-hour overnight fast, subjects were invited to the NRI between 0645 and 
0800. All subjects were also asked to abstain from alcoholic beverages in the night prior to the 
study. The flow of study subjects is given in Figure 2. 
 
Anthropometrics were first measured and recorded. Body composition was assessed by 
bioelectric impedance analysis (BIA) using Tanita Dual Frequency Total Body Composition 
Analyzer (DC-430U, Tokyo, Japan). Measurements were conducted in a standing position, with 
subjects wearing light clothing and without shoes. Height was measured to the nearest 0.1 cm by 
a stadiometer situated against the wall in an upright standing position. Height and weight 
recorded were used to calculate BMI as kg/m2. Standard definitions were used to categorize body 
mass index (BMI) as underweight (BMI<18.5 kg/m2), healthy weight (BMI 18.5-24.9 kg/m2), 
overweight (BMI 25.0-29.9 kg/m2), or obese (BMI≥30 kg/m2). Waist circumference (WC) was 
measured using a stretch-resistance tape at the midpoint between the lower margin of the least 
rib and the top of the iliac crest to the nearest 0.1 inch. Waist-to-height ratio (WHtR) was 
calculated by dividing WC (inch) by height (inch). All the anthropometric measurements were 
taken by one staff member to minimize measurement variation and margin of error. Blood 
pressure was measured using an Omron digital blood pressure monitor (HEM907XL, Omron 
 10 
Healthcare Inc., Lake Forest, IL). Two measurements were taken from the right arm with an 
interval of 1 minute and the average was used for analysis.  
 
Next, subjects were asked to consume a SSB within 10 minutes. The drink was prepared 
by dissolving 60 grams of fructose (Now Foods, Bloomingdale, IL) and 15 grams of glucose 
(Now Foods, Bloomingdale, IL) in 300 mL of water each providing 300 kcal. Glucose was added 
to help alleviate symptoms of gastrointestinal discomfort caused by consuming fructose alone 
(49). Blood was obtained prior to the ingestion and then 30 minutes, 60 minutes, 120 minutes, 
and 180 minutes after the ingestion. Subjects were also asked to complete a questionnaire on 
demographic information, medical history, 24-hour food recall and food frequency information. 
 
Blood processing 
Blood was collected by a trained phlebotomist through venous puncture using 6-mL 
ethylenediaminetetraacetic acid (EDTA)-coated tubes and serum tubes (BD Vacutainer, Becton, 
Dickson & Company, Franklin Lakes, New Jersey). EDTA tubes were placed on wet ice, 
centrifuged at 3000 RPM for 15 minutes at 4°C within 2 hours of collection. Serum, plasma and 
buffy coat were aliquoted and stored at –80°C.  
 
Uric acid and CRP  
At every time point, the concentrations of SUA were measured using fluorometric assays 
according to manufacturer’s instruction (Sigma-Aldrich, St. Louis, MO). CRP was measured at 
all five time points using ELISA (High-sensitivity, DPCR00, R&D Systems, Minneapolis, MN). 
Optical density was measured at wavelengths of 450 nm and 540 nm, using BioTek Synergy 2 
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Multi-Mode plate reader. A four-parameter logistic regression curve was generated as a standard 
curve to calculate the CRP concentrations of unknown samples. All samples were analyzed in 
duplicates. 
 
DNA extraction and SNP genotyping  
DNA was extracted from buffy coat using QIAamp DNA Blood Mini Kit (Qiagen 
Sciences, Valencia, CA). Concentration of genomic DNA was measured using NanoDrop 
Spectrophotometer. SNP rs2231142 of ABCG2 was genotyped using TaqMan SNP Drug 
Metabolism Genotyping Assay (Applied Biosystems, Foster City, CA). In each reaction well, 10 
ng of genomic DNA was mixed with 2X TaqMan Universal PCR Master Mix and 20X Drug 
Metabolism Genotyping Assay Mix, according manufacturer’s instruction. Real-time PCR was 
performed using Eppendorf RealPlex 2 Mastercycler, under the thermal cycling conditions of 
initial hold (95°C, 10 minutes), followed by 50 cycles of denaturation (92°C, 15 seconds) and 
annealing/extension (60°C, 90 seconds). SNPs rs16890979 of SLC2A9 and rs1183201 of 
SLC17A1 were genotyped using TaqMan predesigned SNP genotyping assay (Applied 
Biosystems, Foster City, CA). Each genomic DNA sample (10 ng) was amplified with 2X 
TaqMan Universal PCR Master Mix and corresponding 20X TaqMan SNP genotyping assay. 
Real-time PCR was performed using Eppendorf RealPlex 2 Masterclycler, under the thermal 
cycling conditions of initial hold (95°C, 10 minutes), followed by 50 cycles of denaturation 




All statistical analyses were performed using JMP 13.0 software (SAS Institute, Cary, 
NC). Results in the tables are reported as mean (standard error of the mean). After using Shapiro 
Wilk test to assess normality, non-normal distributed variables were either log-transformed or 
outliers-removed. Equal variance was assessed using Levene’s test. When the equal variance 
assumption was violated, a Welch’s t-test was conducted. The error bars in all figures represent 
standard error of the mean. Variables were compared between genders and obesity status using 
two-tailed t-test. Variables compared between more than 2 groups were analyzed using one-way 
ANOVA, followed by post hoc Student’s t-test to account for each pair comparison. The 
correlations between baseline SUA and metabolic risk factors (including baseline CRP) were 




This study was approved by the Institutional Review Board (IRB) of the University of 
North Carolina at Chapel Hill (study number 16-0876). All subjects provided written informed 
consent before the start of the study. 
 
Results 
Baseline characteristics  
A total of 62 subjects were enrolled in the study, whose characteristics are summarized in 
Table 1. The subjects had a mean ± SEM age of 38.9 ± 0.87 years, BMI of 29.7 ± 0.93 kg/m2, 
baseline SUA concentration of 5.5 ± 0.12 mg/dL and baseline CRP of 0.39 ± 0.07 mg/dL. 
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Women (n=45), compare to men (n=17), had significantly higher percent body fat (p<0.0001), 
lower systolic blood pressure (p=0.002) and baseline SUA (p=0.001). Approximately 60% of the 
subjects were Caucasians, 30% were African-Americans, and the remaining were Hispanics 
(Table 2). When stratified by both gender and ethnicity, means of body weight (p=0.005), BMI 
(p=0.004), percent body fat (PBF) (p<0.0001), waist circumference (p=0.008), waist-to-height 
ratio (WHtR) (p=0.01), systolic blood pressure (p=0.001), baseline uric acid (p=0.005) and CRP 
(p=0.02) differed significantly across 5 ethnic-gender groups (Table 2). Specifically, African-
American women (n=15) had significantly higher adiposity-related variables (body weight, BMI, 
PBF, WC, and WHtR). Caucasian men, on the other hand, had the highest baseline SUA 
(p<0.05). Pearson’s tests showed that SUA was positively correlated with systolic blood pressure 
(SBP) in only Caucasians (r=0.43, p0.0009; Table 3), and CRP was positively correlated with 
adiposity measurements, including BMI (r=0.66, p<0.0001), Percent body fat (r=0.54, p<0.0001), 
WC (r=0.59, p<0.0001) and WHtR (r=0.65, p<0.0001).  
 
Serum uric acid  
Serum uric acid concentration, on average, increased by 0.66 mg/dL in the first 30 
minutes following SSB consumption and then gradually returned towards baseline in the 
remaining 2.5 hours. When adjusted for age and gender, the average concentrations of SUA 
varied significantly by ethnicity (Figure 3). Because of the small sample size, Hispanic were 
excluded from the statistical analysis in this part. Except for the baseline and end point, African-
Americans had significantly lower SUA concentrations than Caucasians (p=0.03 at 30-min, 
p=0.02 at 60-min, p=0.04 at 120 min). Meanwhile, African-Americans and Caucasians exhibited 
significantly different percent change in SUA in the first 30 minutes post-intervention (p=0.002; 
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Figure 3B). Furthermore, men had significantly higher SUA throughout the intervention than 
women, even after accounting for effects of age and race (p=0.001, 0.007, 0.005, 0.005 and 
0.002 at 0-, 30-, 60-, 120- and 180-min; Figure 4A). Surprisingly, instead of the first 30 minutes, 
the last 60 minutes was the time interval when men and women had significantly different 
percent change in SUA (p=0.02; Figure 4B). Precisely, SUA in men increased while SUA in 
women decreased between 120- and 180-min.  
 
The effects of SNPs on SUA during the fructose challenge  
We genotyped three uric acid transporter SNPs and the minor allele frequencies (MAFs) 
of all participants are summarized in Table 4 I and the MAFs stratified by ethnicity are present 
in Table 4 II. In our study, all ethnicities shared the same minor allele for all SNPs except for 
rs16890979, where C was the minor allele among African-Americans while T was the minor 
allele among Caucasians and Hispanics. After adjustment for covariates, SUA and its percent 
change did not differ significantly by genotype (Figure 5). 
 
CRP  
At the baseline, women had higher serum concentrations of CRP than men, though not 
significantly (p=0.16). When ethnicity was taken into consideration, African-American women 
had significantly higher CRP than African American men (p=0.09) and Caucasian women 
(p=0.01). On average, CRP stayed constant during the first 30 minutes then increased by 0.03 
mg/dL and finally restored baseline levels (data not shown). CRP did not differ significantly 
according to gender or race. Nevertheless, obese participants (n=34) had significantly higher 




This is the first dietary challenge study in Caucasians, African-Americans and Hispanics 
to compare serum concentrations of uric acid and CRP following an acute fructose load. Our 
results have demonstrated that in response to the SSB, the variation in SUA concentrations is 
dependent on one’s ethnicity and gender.  
 
SUA concentrations have been observed to rise after eating a large fructose-based meal 
(50) or drinking commercially available soft drinks (51). Indeed, in our study, SUA 
concentrations escalated in the first 30 minutes and then gradually declined to the baseline 
concentrations within 3 hours. In a study by Carran et al. (12), a soft drink as small as 355ml 
showed significant increase in circulating uric acid at 30min as well as 60min time points. When 
considering ethnicity, Caucasians had the highest SUA at baseline and throughout the 
intervention than participants of the other two ethnicities, which was in contrast to the results of 
the African-American Study of Hypertension and Kidney Disease (52). Additionally, after 
adjusting for age and race, there was a pronounced gender-specific difference in SUA 
concentrations at baseline and throughout the fructose challenge. Previous studies (24,26) have 
shown that the gender-specific difference decreased as women age and was eventually lost after 
menopause, implying a role for estrogen in uric acid excretion. In the present study, women 
subjects had a mean age of 39 which was younger than the average age of U.S. women 
experience menopause (53), possibly explaining the observed difference in SUA concentrations. 
In the study conducted by Dalbeth et al. (54), following a fructose load, adults with a BMI 
greater than 25 kg/m2 had higher serum urate than those with a lower BMI throughout the 
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observation period. In the current study, such a distinct response mediated by BMI was observed 
but did not reach statistical significance (data not shown). Interestingly, after adjusting for the 
effects of age, gender and ethnicity, participants with BMIs greater than 30 kg/m2, on average, 
experienced a decrease in SUA during the first 1 hour post-intervention while the non-obese 
counterparts had increased SUA.  
 
Uric acid levels are modulated by numerous factors, including dietary intake of purines 
and fructose, endogenous production and renal and gastrointestinal excretion (55). Genetic 
polymorphisms in urate transporters including ABCG2, SLC2A9 and SLC17A1 are also 
postulated to be a key modulator in multiple ethnic groups. ABCG2 (56), SLC2A9 (57) and 
SLC17A1 (58) are urate transporters located in kidney proximal tubule cells. A missense 
mutation, rs2231142 Q141K, of ABCG2 gene has been shown to be associated with higher uric 
acid levels in Asian (59,60), Europeans (61,62) and New Zealand Pacific Islanders (63). Another 
non-synonymous mutation, rs16890979-SLC2A9 (Val253Ile) showed strong association with 
SUA levels in Amish (64) and American Indians (65). Finally, in Caucasians and Polynesians, 
SLC17A1 polymorphism rs1183201 was strongly associated with gout (66). Given their 
important roles in SUA variation, these three SNPs were genotyped and the genotype-specific 
effects of fructose on SUA were assessed. We found that, even though there was a distinction in 
SUA based on one’s genotype, such responses did not reach statistical significance. Our results 
indicated that the minor allele of rs2231142-ABCG2 was associated with lower levels of SUA. 
Our result is in agreement with a study conducted in European Caucasians and Polynesians (67). 
Unexpectedly, carriers of the minor allele (T) of rs16890979-SLC2A9 had the highest SUA at 
baseline as well as throughout the intervention, albeit not significantly. A genome-wide 
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association study (GWAS) in Caucasians and African-Americans showed a contrasting result 
that the T allele was associated with lower SUA and a lower risk for gout (61). This discrepancy 
could be largely due to the limited sample size of TT carriers. The SNP rs1183201-SLC17A1 is 
the least studied among the 3 SNPs that we investigated in. Dalbeth et al. (68) reported a similar 
result that the A allele was associated with reduced serum urate concentrations following a 
fructose challenge in European Caucasians. However, we observed that the T carriers showed 
lower SUA concentrations throughout the intervention than AA carriers.  
 
Many clinical studies, concerning fructose and systematic inflammation, were published 
in the past years showing conflicting results. Aeberli et al.(23) found in a 3-week intervention 
study that hs-CRP increased significantly after consuming 5 different SSBs. In an acute 
intervention, Jameel et al.(22) reported an overall increase in CRP concentrations in subjects 
who consumed 50 grams of fructose dissolved in 300 mL water. On the other hand, a recent 8-
day randomized crossover trial demonstrated that fructose sweetened beverage did not affect 
CRP significantly (69). In the present study, we observed no evidence to support the hypothesis 
that the SSB elicits a significant increase in CRP concentration. However, CRP concentrations in 
serum do seem to be affected by obesity status. This was expected, as the precursor of CRP – 
interleukin 6 – is produced and released in part by adipose tissue.  
 
Although a handful studies have been conducted to investigate the effect of long-term 
SSB consumption on inflammation, a longer observation period still merits. The main limitation 
of this study is our small sample size, especially in the Hispanic population. A larger sample size 
might be able to detect stronger genotype-specific and ethnic-specific effects of fructose on SUA 
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and CRP. Other limitations of this study include (1) the absence of family history on gout 
because uric acid has been shown to be heritable (70), (2) the SSB composition used in this study 
is not found in commercially available beverages, which are often sweetened with sucrose or 
HFCS, and (3) CRP increases with acute infection and trauma (71), thus subjects who have had 
upper respiratory infection or other acute illness in the past 2-3 weeks should be excluded. 
However, strengths of the study include a fructose challenge which overcome the errors of self-
reported diet intake information and the investigation of ethnic-and genotype-specific differences 
in SUA response to acute fructose load.  
 
Conclusion 
Our pilot study demonstrates that SUA concentrations respond differentially based on 













Table 1 Characteristics at baseline, all subjects1 
 
 Total Men Women p-value
2 
n 62 17 45 
 Age (yrs) 38.9 (0.87) 38.7 (2.03) 39.0 (0.94) 0.72 
Weight (lbs) 185.0 (5.95) 200.1 (8.83) 179.3 (7.36) 0.07 
BMI (kg/m2) 29.7 (0.93) 29.0 (1.22) 30.0 (1.21) 0.80 
PBF (%) 35.0 (1.31) 25.5 (1.99) 38.5 (1.29) <0.0001 
WC (inch) 38.1 (0.86) 39.4 (1.27) 37.6 (1.09) 0.35 
WHtR 0.58 (0.01) 0.57 (0.02) 0.58 (0.02) 0.66 
SBP (mmHg) 115.0 (1.81) 123.1 (2.67) 111.5 (2.10) 0.002 
DBP (mmHg) 73.4 (1.52) 75.4 (3.14) 72.7 (1.74) 0.45 
Uric acid (mg/dL) 5.5 (0.12) 6.17 (0.28) 5.2 (0.11) 0.001 
CRP (mg/dL) 0.39 (0.07) 0.27 (0.11) 0.44 (0.09) 0.16 
 
1. All values present are mean (standard error of the mean). 
2. Reflects comparison between men and women by two-tailed t-test. 
3. Without any covariate adjustment. 
4. Bolded p-values are less than 0.05. 
5. BMI, body mass index; PBF, percent body fat; WC, waist circumference; WHtR, waist-to-





















Table 2 Characteristics at baseline, 5 groups1 
 
 Caucasians  African-Americans  Hispanics  
 Men Women  Men Women  Women p-value
2 
n 12 25  5 15  5  
Age (yrs) 37.9 (2.17) 39.4 (1.28)  40.6 (4.86) 39.6 (1.54)  35.6 (3.26) 0.76 
Wt (lbs) 205.6 (8.24) 160.0 (7.34)  186.9 (23.48) 215.0 (14.01)  169.2 (15.33) 0.005 
BMI (kg/m2) 29.2 (1.34) 26.7 (1.28)  28.5 (2.90) 35.8 (2.15)  28.8 (2.76) 0.004 
PBF (%) 25.6 (2.39) 35.6 (1.75)  25.2 (4.04) 43.5 (1.88)  38.6 (2.73) <0.0001 
WC (in) 39.5 (1.37) 34.8 (1.24)  39.0 (3.06) 42.4 (1.95)  36.5 (1.80) 0.008 
WHtR 0.56 (0.02) 0.54 (0.02)  0.58 (0.04) 0.65 (0.03)  0.57 (0.03) 0.01 
SBP (mmHg) 123.8 (2.62) 109.0 (2.01)  121.4 (7.13) 119.3 (4.66)  100.6 (2.20) 0.001 
DBP (mmHg) 73.8 (3.39) 70.2 (1.28)  79.2 (7.24) 81.0 (3.55)  60.0 (4.34) 0.05 
Uric acid (mg/dL) 6.43 (0.26) 5.2 (0.16)  5.6 (0.67) 5.3 (0.20)  5.2 (0.24) 0.005 
CRP (mg/dL) 0.15 (0.04) 0.23 (0.05)  0.42 (0.21) 0.63 (0.17)  0.76 (0.29) 0.02 
 
1. Means (standard errors of the mean). 
2. Reflects an overall comparison between 5 groups by one-way ANOVA. 
3. Without any covariate adjustment. 
4. Bolded p-values are less than 0.05. 
5. Wt, weight; BMI, body mass index; PBF, percent body fat; WC, waist circumference; WHtR, waist-to-height ratio; SBP, systolic 











Table 3 Correlation of baseline SUA (I) and CRP (II) with metabolic risk factors 
 
I All (n=61)   Caucasians (n=37)   African-Americans (n=20)   Hispanics (n=4) 
Phenotype r (CI) p value 
 
r (CI) p value 
 
r (CI) p value 
 
r (CI) p value 
BMI 0.13 (-0.12, 0.37) 0.31   0.24 (-0.09, 0.52) 0.15   0.11 (-0.35, 0.53) 0.63   0.85 (-0.61, 1.00) 0.15 
PBF -0.16 (-0.4, 0.10) 0.22   -0.24 (-0.52, 0.09) 0.16   0.03 (-0.42, 0.47) 0.90   0.85 (-0.60, 1.00) 0.15 
WC 0.17 (-0.09, 0.40) 0.19   0.22 (-0.11, 0.51) 0.18   0.19 (-0.27, 0.59) 0.42   0.96 (-0.07, 1.00) 0.04 
WHtR 0.1 (-0.16, 0.34) 0.44   0.13 (-0.20, 0.43) 0.45   0.17 (-0.29, 0.57) 0.47   0.99 (0.64, 1.00) 0.01 
SBP 0.16 (-0.09, 0.40) 0.22   0.43 (0.12, 0.66) 0.0009   -0.18 (-0.58, 0.28) 0.44   0.98 (0.28, 1.00) 0.02 
DBP -0.06 (-0.31, 0.19) 0.65   0.17 (-0.16, 0.47) 0.30   -0.39 (-0.71, 0.06) 0.09   0.95 (-0.12, 1.00) 0.05 
0 min CRP 0.12 (-0.14, 0.36) 0.35   -0.02 (-0.34, 0.31) 0.92   0.36 (-0.10, 0.69) 0.12   0.85 (-0.60, 1.00) 0.15 
II All (n=61)   Caucasians (n=37)   African-Americans (n=20)   Hispanics (n=4) 
Phenotype r (CI) p value 
 
r (CI) p value 
 
r (CI) p value 
 
r (CI) p value 
BMI 0.66 (0.49, 0.78) <0.0001   0.45 (0.14, 0.67) 0.006   0.69 (0.36, 0.87) 0.0007   0.98 (0.29, 1.00) 0.02 
PBF 0.54 (0.33, 0.70) <0.0001   0.49 (0.19, 0.70) 0.002   0.50 (0.08, 0.77) 0.02   1.00 (0.99, 1.00) <0.0001 
WC 0.59 (0.40, 0.73) <0.0001   0.46 (0.16, 0.68) 0.004   0.63 (0.26, 0.84) 0.003   0.88 (-0.52, 1.00) 0.12 
WHtR 0.65 (0.47, 0.77) <0.0001   0.52 (0.23, 0.72) 0.001   0.67 (0.33, 0.86) 0.001   0.81 (-0.69, 1.00) 0.19 
SBP -0.12 (-0.36, 0.13) 0.35   -0.11 (-0.42, 0.23) 0.54   -0.29 (-0.65, 0.18) 0.22   0.76 (-0.74, 0.99) 0.24 
DBP 0.08 (-0.17, 0.33) 0.53   0.02 (-0.31, 0.34) 0.90   -0.10 (-0.52, 0.36) 0.67   0.66 (-0.83, 0.99) 0.34 
 
1. Data shown without any adjustment. 
2. Significant p-values are bolded. 
3. r, correlation coefficient; CI, confidence interval; BMI, body mass index; PBF, percent body weight; WC, waist circumference; 






Table 4 Minor allele frequencies of three genotyped SNPs 
 
I SNP Gene AA AB BB MAF 
 rs2231142 ABCG2 GG (52) GT (8) TT (0) 6.67% 
 rs16890979 SLC2A9 CC (32) CT (23) TT (7) 29.8% 
 rs1183201 SLC17A1 TT (34) AT (20) AA (7) 27.9% 
II SNP Race AA AB BB MAF 
 rs2231142 Caucasian 31 6 0 8.1% 
  African-American 19 0 0 0% 
  Hispanic 2 2 0 25.0% 
 rs16890979 Caucasian 25 11 1 17.6% 
  African-American 4 11 5 47.5% 
  Hispanic 3 1 1 30.0% 
 rs1183201 Caucasian 13 17 7 41.9% 
 African-American 17 3 0 7.5% 
 Hispanic 4 0 0 0% 
 
1. A: major allele; B, minor allele. 
2. The numbers showing in the table present the number of participants with each genotype. 






















































Figure 3 Serum uric acid by ethnicity 
 
 
(A) Serum uric acid (mg/dL) vs. time (minute) by ethnicity, adjusted by age and gender; and (B) change in serum uric acid (%) vs. 
time interval (minute) by ethnicty, adjusted by age, gender and WHtR. p<0.05 (*) and p<0.01 (**) by t-test between African-











Figure 4 Serum uric acid by gender 
 
 
(A) Serum uric acid (mg/dL) vs. time (minute) by gender, adjusted by age and ethinicty; and (B) change in uric acid (%) vs. time 





















Figure 6 C-reactive protein by obesity status 
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